Synthetic lethality is a therapeutic strategy specifically investigated for MTAP-deleted cancers, as evidenced by the use of PRMT5 inhibitors like MRTX1719 [1], [2]. Furthermore, researchers have explored the limitations and potential of targeting MTAP-negative cancers through this mechanism [3].